Raeisi T, Rezaie H, Darand M, et al. - Via performing a meta-analysis, researchers sought to resolve the inconsistencies regarding resistin and follistatin levels in women with polycystic ovary syndrome (PCOS). From PubMed and Scopus, they identified a total of 47 publications, 38 for resistin (2424 cases; 1906 controls) and 9 studies for follistatin (815 cases; 328 controls), for inclusion in the meta-analysis. Significantly higher resistin levels were reported in PCOS women vs non-PCOS controls as well as in obese PCOS women vs obese controls, and in non-obese PCOS women vs non-obese controls, but not in obese PCOS vs non-obese PCOS patients. Circulating follistatin was found to be significantly elevated in PCOS patients vs the controls and in non-obese PCOS women vs non-obese controls and in obese PCOS women vs obese controls, but, there was no significant difference in follistatin level in obese PCOS vs non-obese PCOS women. These findings of increased circulating levels of resistin and follistatin, independent of obesity status, in women with PCOS vs controls, suggest a possible contribution of these adipokines to the pathology of PCOS.